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’ INTRODUCTION
In 2007, 23.6 million children and adults in the United States
(7.8% of the population) had diabetes. The pathophysiology of
diabetes is complex, but the main clinical features result from
impairment of insulin secretion and/or function. In humans, the
pancreas is a small, elongated organ that lies behind the stomach
and adjacent to the liver, duodenum, and spleen. The insulin-
producing β-cells that govern glucose homeostasis are located in
the islets of Langerhans, which comprise only 23% of all
pancreatic tissues. β-cells represent up to 80% of the islets, while
other types of cells (mainly R, δ, and pancreatic polypeptide
(PP) cells) contribute to the remaining islet cell mass.
Islet transplantation is a promising treatment option for Type
1 diabetes (T1D) patients; however, the fate of the graft over
time remains difficult to follow, due to the lack of available tools
capable of monitoring islet graft loss. Currently, the estimates of
islet survival and function are limited to indirect assessments
based on exogenous insulin requirements or metabolic studies.
Therefore, the development of noninvasive imaging methods for
the assessment of the pancreatic β-cell mass and status is becom-
ing important for monitoring patients after islet transplantation.
A variety of currently available imaging techniques, including
magnetic resonance imaging (MRI),16 bioluminescence imaging
(BLI),79 and nuclear imaging (positron emission tomography
(PET) and single photon emission computed tomography
(SPECT)), have been tested for the study of β-cells. In particular,
PET is a noninvasive functional imaging technique that provides
adequate resolution, high sensitivity, and accurate quantification
of physiological, biochemical, and pharmacological processes in
living subjects.
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ABSTRACT: Glucagon-like peptide 1 receptor (GLP-1R) is highly
expressed in pancreatic islets, especially on β-cells. Therefore, a pro-
perly labeled ligand that binds to GLP-1R could be used for in vivo
pancreatic islet imaging. Because native GLP-1 is degraded rapidly by
dipeptidyl peptidase-IV (DPP-IV), a more stable agonist of GLP-1 such
as Exendin-4 is a preferred imaging agent. In this study, DO3A-VS-
Cys40-Exendin-4 was prepared through the conjugation of DO3A-VS
with Cys40-Exendin-4. The in vitro binding affinity of DO3A-VS-
Cys40-Exendin-4 was evaluated in INS-1 cells, which overexpress GLP-
1R. After 64Cu labeling, biodistribution studies and microPET imaging
of 64Cu-DO3A-VS-Cys40-Exendin-4 were performed on both subcu-
taneous INS-1 tumors and islet transplantation models. The subcuta-
neous INS-1 tumor was clearly visualized with microPET imaging after
the injection of 64Cu-DO3A-VS-Cys40-Exendin-4. GLP-1R positive organs, such as pancreas and lung, showed high uptake. Tumor
uptake was saturable, reduced dramatically by a 20-fold excess of unlabeled Exendin-4. In the intraportal islet transplantation
models, 64Cu-DO3A-VS-Cys40-Exendin-4 demonstrated almost two times higher uptake compared with normal mice. 64Cu-DO3A-
VS-Cys40-Exendin-4 demonstrated persistent and specific uptake in the mouse pancreas, the subcutaneous insulinoma mouse
model, and the intraportal human islet transplantation mouse model. This novel PET probe may be suitable for in vivo pancreatic
islets imaging in the human.
1588 dx.doi.org/10.1021/bc200132t |Bioconjugate Chem. 2011, 22, 1587–1594
Bioconjugate Chemistry ARTICLE
Glucagon-like peptide 1 (GLP-1) is an incretin peptide re-
leased from the intestine in response to nutrient ingestion; its
binding to the GLP-1 receptor (GLP-1R) augments glucose-
induced insulin secretion from pancreatic β-cells.10,11 Since
GLP-1R is highly expressed in islets, and especially highly
expressed on β-cells, ligands of GLP-1R could be ideal probes
for pancreatic β-cell imaging.12,13 Exendin-4, a peptide hormone
first isolated byDr. John Eng from the saliva of the gila monster in
1992, is especially attractive as an affinity ligand.14,15 Exendin-4
displays biological properties similar to human GLP-1, with
which it shares 53% sequence identity;12 however, it is metabo-
lically much more stable than GLP-1. Previously, Exendin ana-
logues have been labeled with 111In,1620 125I,21 99mTc,18 and
68Ga.18,22 However, most tracers were only evaluated in GLP-1
receptor positive insulinoma with experimental models and in
humans.19,20 To date, imaging of transplanted human β-cells in
humans has been limited to one study of SPECT imaging with
Lys40(Ahx-DTPA-111In)NH2]Exendin-4 in one patient who
received transplants in muscle.23 Here, we report the develop-
ment of 64Cu-labeled Exendin-4 for in vivo imaging of GLP-1
receptor. Cu-64 (t1/2 = 12.7 h) decays by β
+ (20%) and
β emission (37%), as well as electron capture (43%), making
it well-suited for radiolabeling proteins, antibodies, and peptides
for PET imaging.24 In addition to characterizing the perfor-
mance of 64Cu-labeled Exendin-4 in a rodent insulinoma model,
we also explored its feasibility for imaging intraportal islet
transplantation.
’EXPERIMENTAL PROCEDURES
General. All commercially available chemical reagents were
purchased from Aldrich (St. Louis, MO) and used without fur-
ther purification. Cys40-Exendin-4 was synthesized by standard
FMOC chemistry by the Synthetic and Biopolymer Chemistry
Core at City of Hope (Duarte, CA). 1,4,7,10-Tetraazacyclodo-
decane-1,4,7-tris(t-butyl acetate) was purchased from Macrocyc-
lics Inc. (Dallas, TX). 64CuCl2 was obtained from Washington
University (St. Louis, MO) by the 64Ni(p,n)64 Cu nuclear
reaction. 125I-Exendin(939) was purchased from Perkin-Elmer
(Wellesley, MA).
Preparation of DO3A-VS Conjugated Exendin-4 (DO3A-
VS-Cys40-Exendin-4). DO3A-VS (1,4,7-tris(acetic acid)-10-vi-
nylsulfone-1,4,7,10-tetraazacyclododecane) was prepared as pre-
viously reported.25 Cys40-Exendin-4 (0.7 μmol) in 250 μL of
water was added to 0.77 μmol of DO3A-VS in 100 μL of water
(pH 8.0) (Figure1). The solution was stirred under argon
overnight at 25 C and the product was purified by HPLC
(Phenomenex Gemini C18, Torrance, CA; flow = 1 mL/min).
The product was characterized by LTQ FT mass spectrometer
(Thermo, Waltham, MA) (m/z: 4752.30, calcd: 4752.93).
Figure 1. (A) Synthesis and Cu-64 labeling of 64Cu-DO3A-VS-Cys40-Exendin-4. (B) Chemical structure of 64Cu-DO3A-VS-Cys40-Exendin-4.
(C) Sequences of Exendin-4 and GLP-1(736)-amide.
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Radiolabeling of DO3A-VS-Cys40-Exendin-4. DO3A-VS-
Cys40-Exendin-4 (10 μg) was labeled by adding of 74 MBq of
64Cu2+ in 0.1 M sodium acetate buffer (pH 5.5) followed by
45 min of incubation at 43 C. DTPA (10 mM, 5 μL) was added
to chelate unlabeled 64Cu. The radiochemical yield was deter-
mined by radio-ITLC and HPLC (flow = 1 mL/min; the mobile
phase was changed from 95% solvent A [0.1% trifluoroacetic acid
(TFA) in water] and 5% solvent B [0.1% TFA in acetonitrile
(ACN)] (02 min) to 35% solvent A and 65% solvent B at
32 min). 64Cu-DO3A-VS-Cys40-Exendin-4 was purified by C-18
Sep-Pak cartridge, and the eluant was evaporated and reconsti-
tuted in saline for animal studies.
Cells. Rat insulinoma cell line INS-1 (GLP-1R positive, kindly
donated by Dr. Ian Sweet, University of Washington, Seattle,
WA) was maintained under standard conditions: the INS-1
insulinoma cells were grown in RPMI-1640 medium supplemen-
ted with 10% fetal bovine serum (Atlanta Laboratories, Atlanta,
GA), 20 mMHepes, 2 mM L-glutamine, 1 mM sodium pyruvate,
1% antibioticantimycotic solution (Mediatech, Manassas, VA),
and 50 mM 2-mercaptoethanol at 37 C in humidified atmosphere
containing 5% CO2. The INS-1 insulinoma cells were grown in
culture until sufficient cells were available.
Human pancreatic islets were isolated by the Southern
California Islet Cell Resources Center (SC-ICRC, Duarte, CA)
from human pancreata from healthy adult donors with a proper
consent for research use and approval by the Institutional Review
Board of the City of Hope. Islet isolations were performed using
the standard collagenase method for pancreas digestion and islet
purification26 following the operating procedures of the SC-
ICRC. Islets cultured for 4872 h in CMRL1066 based islet
culture medium (Mediatech, Manassas, VA) were used in the
experiments.
In Vitro Cell Binding Assay. The in vitro GLP-1R-binding
affinity and specificity of DO3A-VS-Cys40-Exendin-4 and Ex-
endin-4 were assessed via competitive cell binding assays using
125I-Exendin(939) (PerkinElmer, Waltham, MA) as the GLP-
1R specific radioligand. In detail, INS-1 cells were harvested,
washed three times with phosphate buffered saline (1, Media-
tech, Manassas, VA), and resuspended (2 106 cells/mL) in the
binding buffer.27 Filter multiscreen DV plates (96-well, pore size,
0.65 μm,Millipore, Billerica, MA) were seeded with 105 cells and
incubated with 125I-Exendin(939) (0.74 kBq/well) in the
presence of increasing concentrations of different Exendin-4 ana-
logues (01.0 μmol/L). The truncated Exendin(939) is an
antagonist of GLP-1R and a competitive inhibitor of Exendin-4.
The total incubation volume was adjusted to 200 μL. After the
cells were incubated for 2 h at room temperature, the plates were
filtered through a multiscreen vacuum manifold and washed
three times with binding buffer. The hydrophilic polyvinylide-
nedifluoride (PVDF) filters were collected, and the radioactivity
was determined using a gamma counter. The best-fit 50%
inhibitory concentration (IC50) values for INS-1 cells were cal-
culated by fitting the data with nonlinear regression using
GraphPad Prism (GraphPad Software, La Jolla, CA). Experi-
ments were performed on triplicate samples.
Animals.Male, NOD/SCID mice (the City of Hope Animal
Resource Center, Duarte, CA), 810 weeks old, served as
recipients for insulinoma cells and human islet cells. All animal
experiments were performed in compliance with the Guidelines
for the Care and Use of Research Animals established by the
City of Hope/Beckman Research Institute’s Animal Use
Committee.
Xenograft Tumor Model. NOD/SCID mice were injected
with INS-1 rat insulinoma cells (5 106, suspended in 0.1 mL of
1 phosphate buffered saline) subcutaneously in the thigh.
Tumors were established within 1821 days postinjection.
Blood glucose values were monitored daily and 6% glucose
solution was fed ad libitum once the blood glucose level was
lower than 3.3 mmol/L.
Islet Transplantation. Islets with a diameter of less than 250 μm
were used for transplantation. Islets were transplanted into the
livers of NOD/SCIDmice via the portal vein. Immediately before
intraportal infusion, 1000 islet equivalents were suspended in
200 μL of Hank’s balanced salt solution (Mediatech, Manassas,
VA), and loaded in a 1 mL syringe. Under general anesthesia,
the portal vein was exposed by extra-abdominal repositioning of
the bowel and the islets were infused into the portal vein via a
27-gauge needle.
Biodistribution andMicroPET Imaging. Biodistribution and
microPET imaging of 64Cu-DO3A-VS-Cys40-Exendin-4 were
performed in mice bearing INS-1 tumor or islet grafts to evaluate
the in vivo specific binding to GLP-1R. For blocking studies,
Exendin-4 (20 μg) was coinjected with the radiotracer. For
biodistribution studies, NOD/SCID mice bearing INS-1 tumor
(n = 3, for each time point) were injected intravenously with
64Cu-DO3A-VS-Cys40-Exendin-4 (0.05 μg, 0.37 MBq, 100 μL).
Activity injected into each mouse was measured in a dose
calibrator (Capintec, Ramsey, NJ). Animals were sacrificed under
inhalation anesthesia at 1 h, 4 h, and 22 h postinjection (p.i.).
Tissues and organs of interest were excised and weighed. Radio-
activity in each excised specimen was measured using a gamma
counter; radioactivity uptake was expressed as percent injected
dose per gram (%ID/g). Mean uptake (%ID/g) and correspond-
ing standard deviation was calculated for each group of animals.
For microPET imaging, mice were injected via the tail vein
with 3.77.4 MBq of 64Cu-DO3A-VS-Cys40-Exendin-4 (0.5
1 μg). Serial imaging of INS-1 tumor (at 1, 4, and 22 h; scan
duration 20, 20, and 45 min, respectively) and islet transplanta-
tion model (at 2 and 5 h; scan duration 10 and 20 min,
respectively) was performed using a microPET R4 scanner
(Concorde Microsystems, Knoxville, TN; 8 cm axial field of
view, spatial resolution 2.0 mm). Images were reconstructed with
a MAP iterative algorithm using the microPET Manager software
(Concorde Microsystems, Knoxville, TN). Images were then
analyzed using the Acquisition Sinogram Image Processing
(ASIPro) software (Concorde Microsystems, Knoxville, TN).
Average radioactivity accumulation within liver was obtained
from a three-dimensional region of interest (ROI) drawn within
the central portion of the PET liver image. Image intensities were
converted to units of activity concentration (Bq/cm3) using a
calibration factor obtained by scanning a cylindrical phantom
filled with a known activity concentration of 64Cu. Assuming a
tissue density of 1 g/mL, measured tissue activity concentrations
were converted to units of Bq/g, then multiplied by 100 and
divided by the injected dose to obtain an image-derived percent
injected dose per gram of tissue (% ID/g).
Histology Study. Livers of mice transplanted with human
islets and human pancreas were fixed with 10% formalin and
processed for paraffin embedding. 5 μm parallel sections were
stained with hematoxylin and eosin or immunostained for insulin
and GLP-1R, as described previously.28,29 Guinea pig antihuman
insulin (DAKO, Carpinteria, CA) and rabbit antihuman GLP-1R
(Novus Biologicals, Littleton, CO) were used as primary anti-
bodies. The corresponding secondary antibodies were conjugated
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with FITC or Texas Red (Jackson Immunoresearch,West Grove,
PA). The slices were counter-stained for DNA with diamidino-
phenylindole (DAPI) (Sigma, St. Louis, MO) and visualized
with an Olympus BX51 fluorescent microscope equipped with
a Pixera 600 camera.
Statistical Analysis. Quantitative data were expressed as
mean ( SD. Means were compared using one-way ANOVA
and Student’s t test. P values of <0.05 were considered statisti-
cally significant.
’RESULTS
Chemistry and Radiolabeling. The identity of DO3A-VS-
Cys40-Exendin-4 (Figure 1) was confirmed by HPLC and mass
spectrometry. The 64Cu-labeling (n = 5) was achieved in 64Cu-
DO3A-VS-Cys40-Exendin-4 with more than 95% decay-corrected
yield and radiochemical purity of >99%. 64Cu-DO3A-VS-Cys40-
Exendin-4 was analyzed by ITLC and HPLC. The HPLC reten-
tion time of 64Cu-DO3A-VS-Cys40-Exendin-4 was 23 min. For
radio-TLC analysis, 64Cu-DO3A-VS-Cys40-Exendin-4 remained
at the origin of the TLC plate, while the retention factor (Rf)
value for free 64Cu-DTPA was 0.91.0. The specific activity of
64Cu-DO3A-VS-Cys40-Exendin-4 was around 3.3 1015 Bq/mol.
In Vitro Cell Binding Affinity. We compared the receptor-
binding affinity of DO3A-VS-Cys40-Exendin-4 with that of
Exendin-4 using a competitive cell-binding assay (Figure 2).
Both peptides inhibited the binding of 125I-Exendin(939)
to GLP-1R positive INS-1 cells in a dose-dependent manner.
The IC50 value for DO3A-VS-Cys
40-Exendin-4 (190.6 (
3.5 pmol/L) was comparable to that of Exendin-4 (130.7 (
8.3 pmol/L). The results showed that DO3A conjugation had a
minimal effect on the receptor-binding affinity.
Biodistribution Studies and MicroPET Imaging. The GLP-
1R targeting efficacy and biodistribution patterns of 64Cu-
DO3A-VS-Cys40-Exendin-4 in NOD/SCID mice bearing INS-
1 rat insulinoma xenografts (GLP-1R positive) were evaluated at
multiple time points (1, 4, and 22 h) with static microPET scans.
Representative sliced decay-corrected coronal images at different
time points are shown in Figure 3A. The INS-1 tumors were
clearly visualized with high tumor-to-background contrast for
64Cu-DO3A-VS-Cys40-Exendin-4.
To obtain quantitative biodistribution data, we performed
dissection and direct assay of tissue activity concentration in
groups of insulnoma-bearingmice sacrificed at 1, 4, and 22 h. The
data are shown in Figure 3B. Uptake of 64Cu-DO3A-VS-Cys40-
Exendin-4 in INS-1 insulinomas was 12.7( 2.9, 14.2( 2.6, and
9.2 ( 4.0% ID/g at 1, 4, and 22 h p.i., respectively (Figure 3B).
This result is consistent with the excretion pattern from the
microPET imaging results. Similar to the microPET imaging
result, 64Cu-DO3A-VS-Cys40-Exendin-4 mainly accumulated in
the kidneys, which remained at 46.8 ( 11.4%ID/g at 23 h p.i..
The GLP-1 receptor specificity of 64Cu-DO3A-VS-Cys40-
Exendin-4 was confirmed by a blocking experiment where the
radiotracer was coinjected with excess amount of cold Exendin-4
(20 μg). As can be seen from Figure 4A, in the presence of
unlabeled Exendin-4, the INS-1 tumor uptake was significantly
lower (2.7 ( 2.0% ID/g) than that without Exendin-4 blocking
(14.2 ( 2.6% ID/g, P < 0.01) at 4 h p.i. In the blocking
experiment, the uptake of 64Cu-DO3A-VS-Cys40-Exendin-4 in
other GLP-1 positive organs (pancreas, lungs, and duodenum)
was significantly decreased (Figure 4B).
To test the tracer in an islet transplant model, we implanted
1000 IEQ human islets into mouse liver via portal vein. Nine
days after implantation, mice were imaged with 64Cu-DO3A-
VS-Cys40-Exendin-4 (Figure 5A). Liver uptake of the radio-
tracer was significantly higher (P < 0.01) in transplanted mice
(4.0 ( 0.2 and 5.3 ( 0.7%ID/g at 2 and 5 h p.i., respectively)
than in control mice (1.7( 0.6 and 2.4( 0.8%ID/g at 2 and 5 h
p.i., respectively) (Figure 5B). Histology studies (Figure 6)
clearly demonstrated that human islet grafts were present in
mouse liver and that most insulin-positive cells are also GLP-1R-
positive, which are similar to those for native human islets in the
pancreas. This study confirmed that the higher liver uptake of
Figure 2. Competitive binding assays of 125I-Exendin(939) and
DO3A-VS-Cys40-Exendin-4 or Exendin-4 in INS-1 cells . Data are mean
( SE (n = 3). X axis reflects concentration of nonradolabeled compe-
titor. IC50 values for DO3A-VS-Cys
40-Exendin-4 and Exendin-4 were
190.6 ( 3.5 and 131.07 ( 8.3 pM, respectively.
Figure 3. (A) Representative coronal microPET images of a NOD/SCID mouse bearing an INS-1 xenograft and injected with 64Cu-DO3A-VS-Cys40-
Exendin-4 (arrows point to the tumor; image is saturated if uptake g20%ID/g). (B) Biodistribution of 64Cu-DO3A-VS-Cys40-Exendin-4 in NOD/
SCID mice bearing INS-1 xenograft at 1 h, 4 h, and 23 h p.i.. The data are mean ( SD (n = 3).
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the islet transplantation model was due to a GLP-1R targeting
effect.
’DISCUSSION
Amajor challenge for both experimental diabetes research and
clinical diabetes care is to obtain spatial and quantitative infor-
mation about islet or β-cell mass (BCM). Imaging technology
has advanced rapidly in recent years, making it possible to
noninvasively image small and/or deep structures within the
body. It would be of great benefit to the diabetes community to
be able to image the pancreatic BCM noninvasively. Such a
method would not only facilitate early clinical diagnosis of beta-
cell loss during development of T1D, but also provide an
approach with which to evaluate antidiabetic drugs with the
potential to stimulate β-cell regeneration. Noninvasive imaging
could also be very important for monitoring the fate of trans-
planted islets.
It is difficult to quantify β-cell mass noninvasively due to the
small size (50500 μm in diameter) of islets and their scattered
distribution pattern throughout the pancreas. Therefore, a ligand
with high affinity and specificity for pancreatic β-cells is required.
Several receptors and their ligands have been reported for β-cell
imaging, including sulfonylurea receptor 1 (SUR1),3032 the
vesicular acetylcholine transporter (VAChT),33 and monoamine
transporter 2 (VMAT2);3438 however, most of the imaging re-
sults are suboptimal, and an ideal probe for accurate and
noninvasive imaging of pancreatic β-cells has not yet been
developed.
GLP-1R is highly expressed in islets, especially on β-cells in
the pancreas. Therefore, the ligands of GLP-1R could be ideal
probes for pancreatic β-cell imaging. In this study, 64Cu-DO3A-
VS-Cys40-Exendin-4 was prepared and shown to have high bind-
ing affinity to GLP-1R in vitro. The high and specific expression
of GLP-1R on INS-1 cells makes the rodent insulinomamodel an
Figure 4. (A) Representative coronal microPET images of NOD/SCID mice bearing INS-1 xenograft 4 h after injection of 64Cu-DO3A-VS-Cys40-
Exendin-4 in the absence/presence of excess Exendin-4 (arrows point to the tumors, image is saturated if uptake g20%ID/g). (B) Biodistribution of
64Cu-DO3A-VS-Cys40-Exendin-4 in NOD/SCID mice bearing INS-1 xenograft in the absence/presence of excess Exendin-4 at 4 h p.i. The data are
mean ( SD (n = 3; *P < 0.01, **P < 0.015).
Figure 5. (A) Coronal microPET images of 64Cu-DO3A-VS-Cys40-Exendin-4 in NOD/SCID mice transplanted with human islets into liver or native
NOD/SCID mice (white arrows point to the livers, red arrows point to kidneys, and yellow arrows point to bladders). Images are normalized to reflect
radiodecay-corrected relative image intensity per unit injected activity (image is saturated if uptake g10%ID/g). (B) Image-derived liver uptake
compared between the islet transplantmodel and normal mice. The data are themean( SD (n= 3). Uptake was higher in transplantedmice at both time
points (P < 0.01).
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ideal platform to test the GLP-1R targeting efficacy and speci-
ficity. As expected, the GLP-1R positive INS-1 tumor demon-
strated high and persistent uptake of 64Cu-DO3A-VS-Cys40-
Exendin-4. Receptor specificity was confirmed by a blocking
experiment. The pancreas and lung, which have high GLP-1R
expression, showed relatively high specific uptake. The uptake of
pancreas was reduced by unlabeled Exendin-4 from 5.9 ( 0.8%
ID/g to 1.1( 0.1%ID/g at 4 h p.i. (P < 0.01), and the lung uptake
was reduced from 6.4 ( 2.2%ID/g to 1.8 ( 0.9%ID/g (P <
0.015). It needs to be pointed out that the human lung expressed
significantly smaller amounts of GLP-1 receptor compared with
rodent lung.39
High kidney uptake of 64Cu-DO3A-VS-Cys40-Exendin-4 was
observed in both the microPET imaging and biodistribution
studies, which was similar with other radiometal-labeled Exendin
analogues.1618,22 Previously, other researchers have demon-
strated that GLP-1R has low expression in kidney.3941 It has
been shown that the kidneys are of great importance for the
removal of 64Cu-DO3A-VS-Cys40-Exendin-4 and/or its metabo-
lites from the circulation.42,43 In our research, we have found
64Cu-labeled Exendin-4 was cleared rapidly from blood
(Supporting Information Figure S1) and the high kidney uptake
could not be reduced by the blocking study (coinjection with
nonradiolabeled Exendin-4). L-Polyglutamic acid (PGA), Gelo-
fusine, or the combination of PGA and Gelofusine pretreatment
could significant reduce kidney uptake of Ga-68 labeled Exendin-
4, while the tumor uptake was not affected.18,44 Although 64Cu-
DO3A-VS-Cys40-Exendin-4 is stable in vitro (Supporting Infor-
mation Figure S2-A), metabolites was observed in kidney
homogenate (Supporting Information Figure S2-C). Therefore,
the most likely reason for the high kidney uptake is that
the peptide is filtered through glomerulus and subsequently
degraded by enzymes in the tubuli brush border membrane.42
Human islets were transplanted into NOD/SCID mice livers
through the portal vein, and a subsequent histological study
clearly showed the presence of functional human islets at the time
of imaging. Higher liver uptake was observed with microPET
imaging on day 10 after transplantation compared with that of
normal mice. As shown in Figure 5B, liver uptake in the islet
transplantation model was almost twice that in controls. Thus,
64Cu-DO3A-VS-Cys40-Exendin-4 PET can noninvasively detect
transplanted islets in the liver. It is noted that liver uptake
increased between 2 and 5 h, whichmay be caused bymetabolism
and transchelation of Cu2+ to superoxide dismutase.4548
This is a principle proof study and only a single number of
human islets were transplanted into mice liver and a single time
point microPET scan was performed post islet transplantation.
Further studies are needed to test the feasibility of long-term
monitoring of transplanted islets with 64Cu-DO3A-VS-Cys40-
Exendin-4. In future studies, we will transplant different numbers
of islets into mice liver and perform microPET scan at different
time points post-transplantation to correlate the β-cell mass and
uptake of mice livers.
’CONCLUSION
In summary, GLP-1R targeted 64Cu-DO3A-VS-Cys40-Exen-
din-4 showed high and specific uptake in INS-1 tumors. More-
over, we also demonstrated the feasibility of 64Cu-DO3A-VS-
Cys40-Exendin-4 for in vivo imaging intraportally transplanted
islets in mice. These results suggest that 64Cu-DO3A-VS-Cys40-
Exendin-4 is a very promising PET probe for transplanted islets
imaging and may be useful for clinical translation.
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Figure 6. Human islet grafts in the liver of NOD/SCID mice and native human pancres. Parallel mice liver and human pancreas sections were stained
with hematoxylin/eosin and immunostained for insulin (green), GLP-1R (red), and DNA (blue). Scale bar, 100 μm.
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